Biomerieux tracks worst day in almost a year after EBIT miss

Biomerieux SA

01/09/2023 08:55

** Shares in Biomerieux  BIOX.PA  fall around 4% after the
French diagnostics specialist's H1 operating income misses
market forecasts
    ** Operating income falls 9.5% to 291 mln euros ($315.85
mln) vs analysts' median estimate of 303 mln in a
company-provided poll
    ** "1H sales in-line but 4% EBIT miss," Jefferies comments
    ** Midcap Partners notes that while operating profit fell a
little more than expected, it is due to a 10 mln euro employee
shareholding plan
    ** The shares are on track for worst day since September
2022 and among worst performers on Europe's STOXX 600 index
 .STOXX 

($1 = 0.9213 euros)

 (Reporting by Augustin Turpin)
 ((augustin.turpin@thomsonreuters.com))